Biomarker Services
Customised biomarker panels to enhance all stages of therapeutic development
Innovative Biomarker Analysis Solutions
Synexa Life Sciences has over two decades experience designing biomarker strategies to support customers’ broader clinical development objectives. Our team of scientists are experts in developing optimum biomarker strategies for biomarker discovery, selection and analysis in order to meet your clinical development goals.
Synexa’s global setup aims to support research programs from translational research through to late-stage clinical trials and post-marketing surveillance. Working collaboratively, we focus on careful selection of markers to ensure results that support decision-making and progression through the therapeutic pipeline with confidence.
Specialised Biomarker Services
Advice on the optimal selection of biomarkers in the context of the drug, disease and budget.
Biomarker Assay Development & Validation
Development, optimisation and validation of biomarker assays across a wide range of matrices and technology platforms.
Biomarker Analysis
Biomarker analysis of clinical samples for exploratory or clinical trial settings.
Biomarker Solutions
Comprehensive biomarker solutions, from biomarker discovery through to selection and biomarker assay development
Protein
- AlphaLISA
- CBA
- DELFIA
- ELISA & ELISpot
- Fluorescence and luminescence-based assays
- Gyrolab
- MesoScale
- Nephelometry
- Olink
- Radioimmunoassays
DNA
- Digital PCR (dPCR)
- Electrophoresis
- Pharmacogenetics
- Targeted Sequencing
RNA
- Gene expression array
- NanoString
- RT-qPCR
Cell
- Cell Culture Assays
- Circulating Tumor Cells (CTC)
- Flow Cytometry
- ELISpot
- FluoroSpot
- Fluorescence Microscopy
- Microbiology
- Sorting
Tissue
- Correlative Light and Electron Microscopy (CLEM)
- Multiplex Immunofluorescence
- Organotypic culture
- Super Resolution Microscopy
- Whole Tissue Analysis
Biomarker Platforms
Our technology platforms are robust, reliable and reputable in the clinical field and provide comprehensive and detailed data readouts for your application.
VICTOR® Nivo™
Multimode plate reader supporting fluorescence, luminescence and absorbance-based assays
Waters T-QS LC-MS/MS
Tandem mass spectrometry system for sensitive, quantitative small molecule bioanalysis
Sciex 6500+
Triple quadrupole mass spectrometer for highly sensitive, quantitative bioanalysis
Waters Premier I-Class UPLC
Ultra-performance liquid chromatography system delivering high-resolution compound separation
BD FacsLyric (12 colours)
Automated flow cytometry system enabling reproducible, high-throughput immunophenotyping
MSD S600
High-throughput electrochemiluminescence reader for sensitive multiplex biomarker detection
MSD SQ 120
Compact MSD reader enabling robust electrochemiluminescent immunoassays
Olink Signature q100
Proximity extension assay platform for highly specific, multiplexed protein biomarker profiling
WIZARD2 gammacounter
Gamma counter for sensitive radioisotope detection in ligand binding and PK assays
Biacore T200 GxP SPR
Label-free surface plasmon resonance system for real-time biomolecular interaction and binding kinetics analysis
Envision Xcite
Multimode plate reader supporting luminescence, fluorescence and absorbance-based bioassays
Gyrolab xPlore
Automated nanolitre-scale immunoassay platform for rapid, low-volume protein biomarker analysis
FAQ
What guidelines does Synexa use to validate biomarker assays?
None; Synexa’s biomarker assays are validated as fit for purpose based on their context of use.
Does Synexa offer pre-validated biomarker assays?
Whilst Synexa specialises in the development of complex and custom-designed assays, Synexa does offer pre-validated biomarker assays – depending on the context of use, sample type and duration of the study.
What makes Synexa Life Sciences biomarker specialists?
Biomarker analysis often requires flexible thinking and delivery to account for pre-analytical stability considerations, complex data interpretation and outputs, and fit-for-purpose validations. Our experience enables this and more, delivering high-quality data without the rigidity of PK workflows.
Can Synexa measure low-abundance biomarkers, such as cytokines with low fg-pg/mL ranges?
Yes, we recommend using MSD’s S-PLEX ultrasensitive assay platform for the measurement of analytes at extremely low concentrations or to reduce required sample volume / critical reagent usage.
More on Biomarkers
GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions
EBF OS 2025: My Key Highlights
Where Does Bioanalysis Fit into Drug Discovery Pipelines?
Navigating IVDR in Clinical Trials: What’s Changed, and Why It Matters
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
